Tangible Shareholders Equity: The value shareholders equity less intangible assets.
Latigo Biotherapeutics Inc (LTGO) had Tangible Shareholders Equity of $12.50M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-25.80M |
|
-- |
|
-- |
|
$25.81M |
|
$-25.81M |
|
$0.01M |
|
$-25.80M |
|
$-25.80M |
|
$-25.80M |
|
$-25.80M |
|
$-25.80M |
|
$-25.80M |
|
$-25.81M |
|
$-25.81M |
|
0.94M |
|
0.94M |
|
$-27.59 |
|
$-27.59 |
|
| Balance Sheet Financials | |
$59.20M |
|
$0.46M |
|
$5.56M |
|
$64.76M |
|
$51.58M |
|
-- |
|
$0.68M |
|
$52.26M |
|
$-276.08M |
|
|
Tangible Shareholders Equity |
$12.50M |
$12.50M |
|
0.99M |
|
| Cash Flow Statement Financials | |
$-48.35M |
|
$-0.11M |
|
$33.95M |
|
$69.72M |
|
$55.21M |
|
$-14.51M |
|
$4.12M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.15 |
|
-- |
|
-- |
|
-- |
|
2.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-48.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
9.34% |
|
-206.34% |
|
-39.83% |
|
-206.34% |
|
$12.65 |
|
$-51.83 |
|
$-51.71 |
|